Imaging Biometrics Limited
(“IB” or the “Company”)
Imaging Biometrics Announces Soft Close to Phase 1 Trial of Oral Gallium Maltolate for Relapsed or Refractory Glioblastoma
Elm Grove, WI – July 21, 2025 – Imaging Biometrics, LLC, a leader in quantitative imaging and novel therapeutics for CNS malignancies, today announces a soft close to its Phase 1 clinical trial of oral gallium maltolate (GaM) in adult relapsed or refractory glioblastoma. The trial remains active for currently enrolled participants, with no additional patients being recruited at this time.
This milestone reflects strong early engagement and sufficient enrollment to meet the trial’s statistical and operational objectives. While final internal approvals from the Medical College of Wisconsin Cancer Center are pending, the soft close enables the trial team to transition toward data consolidation, endpoint analysis, and Phase 2 protocol finalization – key steps in advancing the development of oral GaM.
Oral GaM offers a differentiated therapeutic profile: once-daily, at-home dosing, a favorable safety record, and a novel mechanism of action that disrupts iron metabolism in tumor cells. With excellent tolerability, GaM is positioned as a potentially transformative agent in glioblastoma care.
IB is actively evaluating the feasibility of independently financing the phase 2 trial while concurrently exploring strategic partnerships. The Company will provide further updates as the trial progresses toward formal closure and data dissemination.
The Board thanks its investigators, its collaborators at the Medical College of Wisconsin, and the patients who continue to drive this research forward.
–ENDS-
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
|
Imaging Biometrics Ltd Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda Tel: 020 7469 0930 |
|
Peterhouse Capital Limited (Financial Adviser and Broker) Tel: 020 7220 9797 |
About Imaging Biometrics® LLC: IB is a wholly owned subsidiary of Imaging Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com. Follow IB on X, @ImgBiometrics.